montelukast has been researched along with Renal-Insufficiency* in 2 studies
2 other study(ies) available for montelukast and Renal-Insufficiency
| Article | Year |
|---|---|
Radioprotective effects of montelukast, a selective leukotriene CysLT1 receptor antagonist, against nephrotoxicity induced by gamma radiation in mice.
In this study, we evaluated the renal protective effects of montelukast (MLK) against ionizing radiation (IR) induced nephrotoxicity in mice.. Radioprotective effects of MLK were assessed by biochemical analysis including measurements of kidney malondialdehyde (MDA), reduced glutathione (GSH), and serum creatinine and urea levels. Besides, for further evaluation of protective effects of MLK on renal system,. According to our findings, MLK has a potential role to be used as a renal protective agent against gamma radiation in radiotherapy. Topics: Acetates; Animals; Antioxidants; Creatinine; Cyclopropanes; Gamma Rays; Glutathione; Kidney; Leukotriene Antagonists; Male; Malondialdehyde; Mice; Mice, Inbred BALB C; Quinolines; Radiation-Protective Agents; Radiotherapy; Receptors, Leukotriene; Renal Insufficiency; Sulfides | 2020 |
Montelukast ameliorates kidney function and urinary bladder sensitivity in experimentally induced renal dysfunction in rats.
Effect of montelukast on the renal dysfunction induced by cisplatin was investigated. A single dose of cisplatin (7 mg/kg, i.p.) induced nephrotoxicity, which was manifested by increasing the sensitivity of isolated urinary bladder rings to acetylcholine (ACh) together with a significant elevation of serum creatinine, blood urea nitrogen, and lactate dehydrogenase. On the other hand, serum albumin was significantly decreased. Moreover, renal dysfunction was further confirmed by a significant increase in lipid peroxides that were measured as malondialdehyde (MDA) in kidney tissue homogenate. Kidney reduced glutathione (GSH) content and superoxide dismutase (SOD) activity were measured, which were decreased and increased, respectively. Administration of montelukast (10 mg/kg/day, p.o.) 5 days before and 5 days after cisplatin injection significantly ameliorated the renotoxic effects of cisplatin, as judged by a significant reduction in the responses of isolated bladder rings to ACh. The deleterious changes induced by cisplatin treatment in kidney function parameters and oxidative stress markers were significantly mitigated by montelukast treatment.. Montelukast may be a beneficial remedy for cisplatin-induced renal dysfunction. Topics: Acetates; Acetylcholine; Animals; Antineoplastic Agents; Antioxidants; Blood Urea Nitrogen; Cisplatin; Creatinine; Cyclopropanes; Glutathione; Kidney; L-Lactate Dehydrogenase; Lipid Peroxides; Male; Malondialdehyde; Oxidative Stress; Quinolines; Random Allocation; Rats; Rats, Sprague-Dawley; Renal Insufficiency; Serum Albumin; Sulfides; Superoxide Dismutase; Urinary Bladder | 2013 |